Currently, there are 124.63M common shares owned by the public and among those 96.84M shares have been available to trade.
The company’s stock has a 5-day price change of 6.77% and -33.94% over the past three months. MRSN shares are trading -73.08% year to date (YTD), with the 12-month market performance down to -85.02% lower. It has a 12-month low price of $0.26 and touched a high of $2.83 over the same period. MRSN has an average intraday trading volume of 3.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.85%, 2.34%, and -69.17% respectively.
Institutional ownership of Mersana Therapeutics Inc (NASDAQ: MRSN) shares accounts for 47.79% of the company’s 124.63M shares outstanding.
It has a market capitalization of $47.98M and a beta (3y monthly) value of 0.80. The earnings-per-share (ttm) stands at -$0.60. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.47% over the week and 12.81% over the month.
Earnings per share for the fiscal year are expected to decrease by -9.37%, and -1.63% over the next financial year. EPS should shrink at an annualized rate of -11.76% over the next five years, compared to 2.74% over the past 5-year period.
Citigroup coverage for the Mersana Therapeutics Inc (MRSN) stock in a research note released on November 15, 2024 offered a Buy rating with a price target of $5. JP Morgan was of a view on March 19, 2024 that the stock is Neutral, while Wedbush gave the stock Outperform rating on February 29, 2024, issuing a price target of $2- $7. Guggenheim on their part issued Buy rating on February 29, 2024.
